文章：

子宫内膜癌合并子宫腺肌病的分子特征：一项多中心探索性分析

Molecular Signature of Endometrial Cancer with Coexistent Adenomyosis: A Multicentric Exploratory Analysis

原文发布日期：30 October 2023

DOI: 10.3390/cancers15215208

类型: Article

开放获取: 是

英文摘要：

Adenomyosis has been associated with better survival outcomes in women with endometrial cancer. However, although the endometrial cancer patients’ risk stratification has been revolutionized by molecular findings, the impact of the molecular signature on the favorable prognosis of endometrial cancer patients with coexistent adenomyosis is unknown. The aim of our study was to compare the prevalence of molecular groups at poor and intermediate prognosis between endometrial cancer patients with and without coexistent adenomyosis. A multicentric, observational, retrospective, cohort study was performed to assess the differences in the prevalence of p53-abnormal expression (p53-abn) and mismatch repair protein-deficient expression (MMR-d) signatures between endometrial cancer patients with and without coexistent adenomyosis. A total of 147 endometrial cancer patients were included in the study: 38 in the adenomyosis group and 109 in the no adenomyosis group. A total of 37 patients showed the MMR-d signature (12 in the adenomyosis group and 25 in the no adenomyosis group), while 12 showed the p53-abn signature (3 in the adenomyosis group and 9 in the no adenomyosis group). No significant difference was found in the prevalence of p53-abn (p= 1.000) and MMR-d (p= 0.2880) signatures between endometrial cancer patients with and without coexistent adenomyosis. In conclusion, the molecular signature does not appear to explain the better prognosis associated with coexistent adenomyosis in endometrial cancer patients. Further investigation of these findings is necessary through future larger studies.

摘要翻译： 

子宫腺肌病与子宫内膜癌患者较好的生存结局相关。然而，尽管分子学发现已彻底改变了子宫内膜癌患者的风险分层，但分子标志物对合并子宫腺肌病的子宫内膜癌患者良好预后的影响尚不明确。本研究旨在比较合并与不合并子宫腺肌病的子宫内膜癌患者中，预后不良和中等的分子组别患病率差异。我们开展了一项多中心、观察性、回顾性队列研究，评估合并与不合并子宫腺肌病的子宫内膜癌患者中p53异常表达（p53-abn）和错配修复蛋白缺陷表达（MMR-d）标志物患病率的差异。研究共纳入147例子宫内膜癌患者：其中38例属于腺肌病组，109例属于非腺肌病组。共有37例患者呈现MMR-d标志物（腺肌病组12例，非腺肌病组25例），12例呈现p53-abn标志物（腺肌病组3例，非腺肌病组9例）。合并与不合并子宫腺肌病的子宫内膜癌患者在p53-abn（p=1.000）和MMR-d（p=0.2880）标志物患病率方面未发现显著差异。综上所述，分子标志物似乎不能解释子宫内膜癌患者合并子宫腺肌病时预后较好的现象。未来需要通过更大规模的研究对这些发现进行进一步验证。

原文链接：

Molecular Signature of Endometrial Cancer with Coexistent Adenomyosis: A Multicentric Exploratory Analysis